CTMX (CytomX Therapeutics) Cyclically Adjusted Revenue per Share: $1.33 (As of Mar. 2026)


CTMX CytomX Therapeutics Inc CTMX
36 GF Score
Price $3.82
GF Value $0.28
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CytomX Therapeutics Cyclically Adjusted Revenue per Share?

CytomX Therapeutics CTMX +6.41% 36 Cyclically Adjusted Revenue per Share is $1.33 as of Mar. 2026. GuruFocus rates CTMX with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

CytomX Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was $0.058. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.33 for the trailing ten years ended in Mar. 2026.

During the past 12 months, CytomX Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-04), CytomX Therapeutics's current stock price is $3.82. CytomX Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $1.33. CytomX Therapeutics's Cyclically Adjusted PS Ratio of today is 2.87.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of CytomX Therapeutics was 4.34. The lowest was 0.35. And the median was 1.63.


CytomX Therapeutics  (NAS:CTMX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

CytomX Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.82/1.33
=2.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of CytomX Therapeutics was 4.34. The lowest was 0.35. And the median was 1.63.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


CytomX Therapeutics Cyclically Adjusted Revenue per Share Related Terms


CytomX Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for CytomX Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytomX Therapeutics Cyclically Adjusted Revenue per Share Chart

CytomX Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.23 1.31

CytomX Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.30 1.31 1.32 1.31 1.33

CTMX vs ALLO, XOMA, OCS: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, CytomX Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytomX Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Cyclically Adjusted PS Ratio falls into.


CTMX
36GF Score
CytomX Therapeutics Inc CTMX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytomX Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CytomX Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.058/330.2130*330.2130
=0.058

Current CPI (Mar. 2026) = 330.2130.

CytomX Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.086 241.018 0.118
201609 0.095 241.428 0.130
201612 0.172 241.432 0.235
201703 0.319 243.801 0.432
201706 0.238 244.955 0.321
201709 0.653 246.819 0.874
201712 0.705 246.524 0.944
201803 0.367 249.554 0.486
201806 0.548 251.989 0.718
201809 0.285 252.439 0.373
201812 0.254 251.233 0.334
201903 0.653 254.202 0.848
201906 0.199 256.143 0.257
201909 0.236 256.759 0.304
201912 -0.491 256.974 -0.631
202003 1.054 258.115 1.348
202006 0.361 257.797 0.462
202009 0.385 260.280 0.488
202012 -0.334 260.474 -0.423
202103 0.262 264.877 0.327
202106 0.250 271.696 0.304
202109 0.270 274.310 0.325
202112 -0.192 278.802 -0.227
202203 0.138 287.504 0.159
202206 0.196 296.311 0.218
202209 0.169 296.808 0.188
202212 0.304 296.797 0.338
202303 0.355 301.836 0.388
202306 0.372 305.109 0.403
202309 0.326 307.789 0.350
202312 0.326 306.746 0.351
202403 0.502 312.332 0.531
202406 0.296 314.175 0.311
202409 0.392 315.301 0.411
202412 0.444 315.605 0.465
202503 0.584 319.799 0.603
202506 0.145 322.561 0.148
202509 0.036 324.800 0.037
202512 0.004 324.054 0.004
202603 0.058 330.213 0.058

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.33 mean?
CytomX Therapeutics (CTMX) has a Cyclically Adjusted Revenue per Share of $1.33 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on CytomX Therapeutics and its competitors.
Is CytomX Therapeutics' Cyclically Adjusted Revenue per Share too high?
CytomX Therapeutics' current Cyclically Adjusted Revenue per Share is $1.33. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Cyclically Adjusted Revenue per Share compare to ALLO and XOMA?
CytomX Therapeutics' Cyclically Adjusted Revenue per Share of $1.33 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on CytomX Therapeutics and its competitors. CytomX Therapeutics's current Cyclically Adjusted Revenue per Share is $1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.82 — trading 1264.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $1.33. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Cyclically Adjusted Revenue per Share is $1.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytomX Therapeutics (CTMX) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of $3.82 is trading 1264.3% above its estimated GF Value™ of $0.28. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for CTMX:

  • Cyclically Adjusted Revenue per Share: $1.33
  • GF Value™: $0.28 vs. price of $3.82 (1264.3% above fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CytomX Therapeutics Business Description

Other Exchanges 6C1:Germany
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score

Get the complete analysis for CTMX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.82
Price
$0.28
GF Value